Yuyuan Lv, Xin Zhang, Qingya Cui, Mengyun Li, Lian Bai, Yan Yu, XueKai Li, Xiaoqian Chen, Depei Wu, Xiaowen Tang
{"title":"包括依拉瓦环素在内的联合治疗对长期严重粒细胞缺乏症合并恶性血液病患者耐碳青霉烯肠杆菌血流感染伴器官播散的有效管理。","authors":"Yuyuan Lv, Xin Zhang, Qingya Cui, Mengyun Li, Lian Bai, Yan Yu, XueKai Li, Xiaoqian Chen, Depei Wu, Xiaowen Tang","doi":"10.1007/s40121-025-01206-2","DOIUrl":null,"url":null,"abstract":"<p><p>This study reports three patients with hematologic malignancy patients and Carbapenem-resistant Enterobacterales (CRE) bloodstream infections and organ dissemination during neutropenia. After failed conventional therapy, a novel \"through Combination therapies including eravacycline\" regimen achieved fever control within 10 days and lesion resolution by 20 days approximately, demonstrating breakthrough efficacy for CRE bacteremia management.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"2465-2476"},"PeriodicalIF":5.3000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12480215/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.\",\"authors\":\"Yuyuan Lv, Xin Zhang, Qingya Cui, Mengyun Li, Lian Bai, Yan Yu, XueKai Li, Xiaoqian Chen, Depei Wu, Xiaowen Tang\",\"doi\":\"10.1007/s40121-025-01206-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study reports three patients with hematologic malignancy patients and Carbapenem-resistant Enterobacterales (CRE) bloodstream infections and organ dissemination during neutropenia. After failed conventional therapy, a novel \\\"through Combination therapies including eravacycline\\\" regimen achieved fever control within 10 days and lesion resolution by 20 days approximately, demonstrating breakthrough efficacy for CRE bacteremia management.</p>\",\"PeriodicalId\":13592,\"journal\":{\"name\":\"Infectious Diseases and Therapy\",\"volume\":\" \",\"pages\":\"2465-2476\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12480215/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Diseases and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40121-025-01206-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-025-01206-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.
This study reports three patients with hematologic malignancy patients and Carbapenem-resistant Enterobacterales (CRE) bloodstream infections and organ dissemination during neutropenia. After failed conventional therapy, a novel "through Combination therapies including eravacycline" regimen achieved fever control within 10 days and lesion resolution by 20 days approximately, demonstrating breakthrough efficacy for CRE bacteremia management.
期刊介绍:
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.